You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Danicopan - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for danicopan and what is the scope of patent protection?

Danicopan is the generic ingredient in one branded drug marketed by Alexion Pharms Inc and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Danicopan has one hundred and seven patent family members in twenty-four countries.

One supplier is listed for this compound.

Summary for danicopan
International Patents:107
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 24
Patent Applications: 40
What excipients (inactive ingredients) are in danicopan?danicopan excipients list
DailyMed Link:danicopan at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for danicopan
Generic Entry Date for danicopan*:
Constraining patent/regulatory exclusivity:
TREATMENT OF EXTRAVASCULAR HEMOLYSIS (EVH) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for danicopan

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Allergy and Infectious Diseases (NIAID)Phase 2
Alexion PharmaceuticalsPhase 3
CelerionPhase 1

See all danicopan clinical trials

US Patents and Regulatory Information for danicopan

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alexion Pharms Inc VOYDEYA danicopan TABLET;ORAL 218037-001 Mar 29, 2024 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Alexion Pharms Inc VOYDEYA danicopan TABLET;ORAL 218037-002 Mar 29, 2024 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Alexion Pharms Inc VOYDEYA danicopan TABLET;ORAL 218037-001 Mar 29, 2024 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for danicopan

Country Patent Number Title Estimated Expiration
Japan 2018199714 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 (ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS) ⤷  Sign Up
Japan 6537532 ⤷  Sign Up
Israel 301427 תרכובות אריל, הטרואריל והטרוציקליות לטיפול בהפרעות מתווכות משלימות (Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.